Bayer drug gets orphan label

Share this article:
Bayer drug gets orphan label
Bayer drug gets orphan label

Bayer HealthCare landed an orphan-drug designation for its experimental inhaled ciprofloxacin dry powder, designed to treat patients with non-cystic fibrosis bronchiectasis.

The condition, which occurs in patients who do not have cystic fibrosis, refers to bronchial tube scarring and inflammation, which make it difficult to clear mucous. The British Lung Foundation estimates that around 25% of cases have no known cause, but some cases are associated with scarring caused by whooping cough or pneumonia and reduced immunity after an infection, among other causes.

Symptoms include recurring infections and a persistent cough.

Bayer's proposed treatment is for intermittent use.

Recently approved orphan drugs include the likes of Eli Lilly's oncology treatment Cyramza.

Share this article:

Email Newsletters

More in News

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.

Amgen Q2 sales rise, company to lay off up to 2,900

Amgen Q2 sales rise, company to lay off ...

The majority of the layoffs will be in the US.

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...